GenSight Biologics S.A. (OTCMKTS:GSGTF – Get Free Report) fell 25% during trading on Wednesday . The company traded as low as $0.24 and last traded at $0.24. 4,012 shares were traded during trading, an increase of 588% from the average session volume of 583 shares. The stock had previously closed at $0.32.
GenSight Biologics Trading Down 25.0 %
The firm’s fifty day simple moving average is $0.32 and its two-hundred day simple moving average is $0.34.
GenSight Biologics Company Profile
GenSight Biologics SA, a clinical-stage biotechnology company, discovers, develops, and commercializes therapies for mitochondrial and neurodegenerative retinal diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms.
Read More
- Five stocks we like better than GenSight Biologics
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Work and Play: Investing in the Rise of Bleisure Travel
- How Can Investors Benefit From After-Hours Trading
- Top Dividend Stocks to Buy Now as Bond Yields Could Lower
- How to Read Stock Charts for Beginners
- SAP: AI Tailwinds Accelerating Enterprise Cloud Business
Receive News & Ratings for GenSight Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenSight Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
